<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848535</url>
  </required_header>
  <id_info>
    <org_study_id>ABRnr42438</org_study_id>
    <secondary_id>WUR42438</secondary_id>
    <nct_id>NCT01848535</nct_id>
  </id_info>
  <brief_title>Effect of GOS Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults</brief_title>
  <acronym>GOS</acronym>
  <official_title>Effect of Galacto-Oligosaccharides Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults : a Proof of Principal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prebiotics are thought to be a potential means to prevent antibiotic-associated diarrhoea&#xD;
      because of their ability to stimulate beneficial bacteria. In-vitro results showed a&#xD;
      promising recovery of Bifidobacteria combined with an increase of Short Chain Fatty Acids&#xD;
      (SCFA) upon Galacto-oligosaccharides (GOS) supplementation to amoxicillin-treated microbiota.&#xD;
      As the microbiota is nowadays considered as a key factor in human health, a further&#xD;
      understanding of the gut microbiota functioning in-vivo is essential. This understanding of&#xD;
      the use of specific prebiotics may possibly be beneficial in the prevention or recovery of&#xD;
      antibiotic-disturbed microbiota. As the effects of GOS supplementation on the microbiota&#xD;
      composition and activity from healthy adults receiving amoxicillin have never been tested&#xD;
      in-vivo, the investigators propose the current study as a proof of principle.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To explore whether the promising effects of GOS supplementation on the composition and&#xD;
      activity of gut microbiota from healthy adults as found by in-vitro, can also be observed&#xD;
      in-vivo.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      10 healthy men and women volunteers, 18 - 40 yr old&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiota composition</measure>
    <time_frame>evaluation between july and september 2013</time_frame>
    <description>Microbiota composition of the collected faecal sample will be investigated using a phylogenetic microarray, the Intestinal-Chip. With this microarray, more than 400 species of the intestinal microbiota can be detected.&#xD;
Bifidobacteria and Lactobacillus as beneficial bacteria as well as Enterobacteriaceae and possible other pathogens (Cells/ g faecal dry weight) will also be measured using a real-time PCR with specific primers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiota activity</measure>
    <time_frame>evaluation between july and september 2013</time_frame>
    <description>The Short Chain Fatty acid (SCFA) amount produced will be measured using chromatographic approaches (Gas Chromatography, High Performance Liquid Chromatography).&#xD;
The remaining GOS will be measured with High Performance Anion Exchange Chromatography (HPAEC) or with Capillary Electrophoresis -Light Induced Fluorescence, which has a better resolution than HPAEC.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gastrointestinal complains</measure>
    <time_frame>during the study (26 day) via a diary</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Colonic Diseases [C06.405.469.158]</condition>
  <arm_group>
    <arm_group_label>GOS addition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (maltodextrine)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GOS addition</intervention_name>
    <description>GOS (2.5g 3x per day) supplemented during 12 days</description>
    <arm_group_label>GOS addition</arm_group_label>
    <arm_group_label>placebo (maltodextrine)</arm_group_label>
    <other_name>Galacto-oligosaccharide</other_name>
    <other_name>Vivinal GOS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrine(2.5g 3x per day) supplemented during 12 days</description>
    <arm_group_label>GOS addition</arm_group_label>
    <arm_group_label>placebo (maltodextrine)</arm_group_label>
    <other_name>maltodextrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-40 *&#xD;
&#xD;
          -  BMI: 18.5-25 kg/m2&#xD;
&#xD;
          -  Stable weight over the last 6 months&#xD;
&#xD;
          -  Western diet&#xD;
&#xD;
          -  Availability of information about birth by caesarean section and breast-feeding&#xD;
&#xD;
          -  Regular defecation (~1day)&#xD;
&#xD;
          -  Healthy as judge by the participant himself&#xD;
&#xD;
          -  Having signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking or drug use&#xD;
&#xD;
          -  Pregnant (include planning to be or gave birth in the last 6 months) or lactating&#xD;
             woman&#xD;
&#xD;
          -  Using contraceptive pill&#xD;
&#xD;
          -  Gastro-intestinal diseases (e.g. irritable bowel syndrome, inflammatory bowel disease)&#xD;
&#xD;
          -  Traveling to an Asian, African or south American country &lt; 6 months before the study&#xD;
&#xD;
          -  Hypersensitivity or food allergy for products used in this study (e.g. Lactose,&#xD;
             Penicillin)&#xD;
&#xD;
          -  Having hepatic disease and renal failure&#xD;
&#xD;
          -  Using medication other than paracetamol, acetylsalicylic acid (aspirin), hay fever,&#xD;
             asthma&#xD;
&#xD;
          -  Not willing to have the family doctor be informed about participation to the study.&#xD;
&#xD;
          -  Antibiotic use &lt; 3 months before the study&#xD;
&#xD;
          -  More than 3 antibiotic treatments in the last 2 years.&#xD;
&#xD;
          -  Probiotic or prebiotic use &lt; 1 month before the study*&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Ladirat, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory of Food Chemistry</name>
      <address>
        <city>Wageningen</city>
        <zip>6703HD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Saulnier DM, Kolida S, Gibson GR. Microbiology of the human intestinal tract and approaches for its dietary modulation. Curr Pharm Des. 2009;15(13):1403-14. Review.</citation>
    <PMID>19442165</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>November 19, 2013</last_update_submitted>
  <last_update_submitted_qc>November 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intestinal microbiota composition</keyword>
  <keyword>intestinal microbiota activity</keyword>
  <keyword>gastro-intestinal complains</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

